Sharon Bae
Internal Medicine · Newport Beach, CANPI 1346211372
Payments from drug & device makers
Across 128 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$594
- Amgen$436
- AbbVie$245
- Sobi, Inc$163
- Johnson & Johnson$145
- Sanofi$138
- plus $976 from 21 others
What the payments were for
- Food & beverage$2,55495%
- Education$1435%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $594 |
| Amgen(2 entities) | 20 | $436 |
| AbbVie(2 entities) | 12 | $245 |
| Sobi, Inc | 9 | $163 |
| Johnson & Johnson | 8 | $145 |
| Sanofi | 7 | $138 |
| AstraZeneca(2 entities) | 6 | $123 |
| Sanofi Pasteur Inc. | 3 | $109 |
| Bristol Myers Squibb | 4 | $82 |
| Currax Pharmaceuticals LLC | 4 | $78 |
| Radius Health, Inc. | 3 | $74 |
| Boehringer Ingelheim | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Nalpropion Pharmaceuticals LLC | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Bausch Health US, LLC | 2 | $31 |
| Merck | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Eisai Inc. | 1 | $24 |
| Medexus Pharma, Inc. | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Pfizer | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,697 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $3,615 |
| Rosuvastatin Calcium | 93 | $1,934 |
| SynthroidLevothyroxine Sodium | 28 | $1,610 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,375 |
| Metoprolol Succinate | 43 | $1,347 |
| Tamsulosin Hcl | 31 | $1,032 |
| Telmisartan | 26 | $923 |
| Atorvastatin Calcium | 103 | $828 |
| Gabapentin | 27 | $816 |
| Amlodipine Besylate | 88 | $758 |
| ValacyclovirValacyclovir Hcl | 24 | $639 |
| Losartan Potassium | 57 | $628 |
| Escitalopram Oxalate | 50 | $606 |
| Levothyroxine Sodium | 59 | $580 |
| Zolpidem Tartrate | 67 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $245 | $1,61028 claims |
| PfizerPaxlovid | $17 | $015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Ryan KleinNewport Beach$5M
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.